- Home
- AGL vs MNKD Comparison
AGL vs MNKD Comparison
Compare AGL & MNKD Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AGL | MNKD |
|---|---|---|
| Founded | 2016 | 1991 |
| Country | United States | United States |
| Employees | 856 | N/A |
| Industry | Managed Health Care | Biotechnology: Pharmaceutical Preparations |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.7B | 1.2B |
| IPO Year | 2021 | 2004 |
Fundamental Metrics
Financial Performance| Metric | AGL | MNKD |
|---|---|---|
| Price | $110.06 | $3.85 |
| Analyst Decision | Hold | Buy |
| Analyst Count | 12 | 8 |
| Target Price | ★ $55.68 | $8.69 |
| AVG Volume (30 Days) | 243.5K | ★ 4.9M |
| Earning Date | 05-06-2026 | 05-06-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ N/A | N/A |
| EPS | ★ 2.94 | N/A |
| Revenue | ★ $5,932,576,000.00 | $348,966,000.00 |
| Revenue This Year | N/A | $35.81 |
| Revenue Next Year | $4.23 | $11.89 |
| P/E Ratio | $35.81 | ★ N/A |
| Revenue Growth | N/A | ★ 22.23 |
| 52 Week Low | $0.30 | $2.23 |
| 52 Week High | $118.25 | $6.51 |
Technical Indicators
Market Signals| Indicator | AGL | MNKD |
|---|---|---|
| Relative Strength Index (RSI) | 67.37 | 61.39 |
| Support Level | $0.62 | $3.30 |
| Resistance Level | N/A | $3.94 |
| Average True Range (ATR) | 9.42 | 0.21 |
| MACD | -0.85 | 0.02 |
| Stochastic Oscillator | 77.59 | 74.83 |
Price Performance
Historical ComparisonAbout AGL agilon health inc.
Agilon Health Inc is a healthcare services company that partners with primary care physicians to support value-based care for senior patients. The company provides a platform that enables physician groups to manage healthcare outcomes and costs through a Medicare-centric, capitated care model and long-term partnerships with community-based physicians.
About MNKD MannKind Corporation
MannKind Corp is a biopharmaceutical company focused on the development and commercialization of patient-centric therapies that address serious unmet medical needs for those living with cardiometabolic and orphan lung diseases. The Company is currently commercializing three products: Afrezza (insulin human) Inhalation Powder, an ultra rapid-acting inhaled insulin indicated to improve glycemic control in adults with diabetes; Furoscix (furosemide injection), to treat fluid buildup in patients with chronic heart failure or chronic kidney disease; and the V-Go wearable insulin delivery device, which provides continuous subcutaneous infusion of insulin in adults that require insulin.